[go: up one dir, main page]

WO2015131176A1 - Compositions, procédés et trousses pour le traitement du cancer - Google Patents

Compositions, procédés et trousses pour le traitement du cancer Download PDF

Info

Publication number
WO2015131176A1
WO2015131176A1 PCT/US2015/018265 US2015018265W WO2015131176A1 WO 2015131176 A1 WO2015131176 A1 WO 2015131176A1 US 2015018265 W US2015018265 W US 2015018265W WO 2015131176 A1 WO2015131176 A1 WO 2015131176A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cell
host cells
composition
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/018265
Other languages
English (en)
Inventor
Eckhard R. Podack
Taylor Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015131176A1 publication Critical patent/WO2015131176A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Definitions

  • Cancer is a disease in which abnormal cells divide without proper control and are able to invade other tissues, spreading to other parts of the body through the blood and lymphatic systems.
  • cancer remains one of the leading causes of morbidity and death in developed countries.
  • treatments presently available for cancer including chemotherapy, radiation therapy, surgical intervention, and the use of various therapeutic agents including, for example, natural products, derivatives of natural products, and synthetic compounds.
  • standard treatment of most aggressive tumors continues to be surgical resection, chemotherapy, and radiotherapy. While increasingly successful, each of these treatments still causes numerous undesired side effects.
  • lung cancer is one of the leading causes of cancer-related mortality in the United States.
  • the ACS estimated that there would be 224,210 new cases of lung cancer diagnosed in the United States alone in 2014, with almost 160,000 lung cancer-related deaths.
  • the present application provides compositions and methods for the treatment of cancer. More particularly, the inventors have developed novel compositions containing a combination of active agents, and a method for treating cancer that includes administering the active agents in combination.
  • this document is based at least in part on the development of treatments that include administering to a patient a composition containing multiple active agents.
  • this document is based in part on the discovery that administration to a patient of a modified heat shock protein in combination with (a) one or more checkpoint inhibitors, (b) one or more T cell co- stimulators, or (c) one or more checkpoint inhibitors and one or more T cell co- stimulators leads to a surprising increase in the expansion of tumor specific CD8+ T cells, which, in turn, provides effective cancer treatment.
  • compositions and methods provided herein may be very valuable in the treatment of cancer, as their use may provide greater efficacy and/or potency, resulting in improved therapeutic response, diminished side effects, or both, as compared to using traditional cancer therapeutics.
  • this document features a method of treating a cancer in a human subject, where the method includes administering to the subject a therapeutically effective amount of a vaccine containing a plurality of host cells, each of the host cells co-expressing at least one tumor antigen and a heat shock protein modified to be secreted from each of the host cells, and a composition containing one or more T-cell co- stimulators.
  • this document features a method of treating a cancer in a human subject, where the method includes administering to the subject a therapeutically effective amount of (a) a vaccine containing a plurality of host cells, each of the host cells co-expressing at least one tumor antigen and a heat shock protein modified to be secreted from each of the host cells, (b) a composition containing one or more checkpoint inhibitors, and (c) a composition containing one or more T-cell co- stimulators.
  • the one or more T-cell co-stimulators can be selected from the group consisting of B7-1, B7-2, B7-h/B7rp- l, CD48, GITR, ICAM-1, ICAM-2, ICAM- 3, LFA-1, LFA-2, LFA-3, VLA-1, VCAM-1, CD30 Ligand (CD30L), CD40 Ligand (CD40L), 4- IBB Ligand (4-1BBL), OX40 ligand, CD70, CD24, LIGHT, and other cell adhesion proteins and other cell surface proteins that can activate T cell co-stimulatory pathways through T cell surface proteins.
  • the one or more T-cell co-stimulators can be OX40 ligand, or can be 4- IBB Ligand.
  • the one or more checkpoint inhibitors can be selected from the group consisting of CTLA-4, PD-1, PD-L1, LAG-3, IDO, TGF-beta, and TIM-3.
  • this document features a composition containing a vaccine that contains a plurality of host cells, each of the host cells co-expressing at least one tumor antigen and a heat shock protein modified to be secreted from each of the host cells, and one or more checkpoint inhibitors.
  • modified heat shock proteins are administered to a patient in combination with one or both of:
  • modified hsps can be produced by various methods known in the art.
  • the manipulations that result in their production can occur at the gene or protein level, but manipulations at the gene level can be particularly useful.
  • the cloned coding region of an hsp can be modified by any of numerous recombinant DNA methods known in the art (see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d ed., 1990, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and Ausubel et al, in Chapter 8 of Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley Interscience, New York).

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés, des trousses et des compositions destinés à traiter le cancer. Le traitement consiste à administrer à un patient nécessitant un tel traitement une combinaison formée d'une protéine de choc thermique modifiée et de : (a) un ou plusieurs inhibiteurs de point de contrôle; (b) un ou plusieurs co-stimulateurs des lymphocytes T; ou c) un ou plusieurs inhibiteurs de point de contrôle et un ou plusieurs co-stimulateurs des lymphocytes T.
PCT/US2015/018265 2014-02-28 2015-03-02 Compositions, procédés et trousses pour le traitement du cancer Ceased WO2015131176A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946609P 2014-02-28 2014-02-28
US61/946,609 2014-02-28

Publications (1)

Publication Number Publication Date
WO2015131176A1 true WO2015131176A1 (fr) 2015-09-03

Family

ID=54009703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/018265 Ceased WO2015131176A1 (fr) 2014-02-28 2015-03-02 Compositions, procédés et trousses pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2015131176A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016110593A1 (fr) * 2015-01-09 2016-07-14 Immutep S.A.S. Préparations combinées pour le traitement d'un cancer ou d'une infection
US9644032B2 (en) 2015-05-29 2017-05-09 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
EP3253876A4 (fr) * 2015-02-06 2018-09-19 Heat Biologics, Inc. Vecteur co-exprimant un vaccin et des molécules co-stimulantes
US10736940B2 (en) 2013-12-19 2020-08-11 Immutep S.A.S. Combined preparations for the treatment of cancer
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
US11648223B2 (en) * 2016-06-10 2023-05-16 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297154A1 (en) * 1998-07-02 2010-11-25 Genitrix, Llc CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen
US20120034242A1 (en) * 2003-04-02 2012-02-09 Biosante Pharmaceuticals, Inc. Cytokine-expressing cellular vaccine combinations
US20130045202A1 (en) * 2008-12-09 2013-02-21 Genentech, Inc. Anti-pd-l1 antibodies and articles of manufacture
US20130302376A1 (en) * 2008-03-03 2013-11-14 Nozomi Yamazaki Allogeneic Cancer Cell-based Immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297154A1 (en) * 1998-07-02 2010-11-25 Genitrix, Llc CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen
US20120034242A1 (en) * 2003-04-02 2012-02-09 Biosante Pharmaceuticals, Inc. Cytokine-expressing cellular vaccine combinations
US20130302376A1 (en) * 2008-03-03 2013-11-14 Nozomi Yamazaki Allogeneic Cancer Cell-based Immunotherapy
US20130045202A1 (en) * 2008-12-09 2013-02-21 Genentech, Inc. Anti-pd-l1 antibodies and articles of manufacture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAPECE ET AL.: "Targeting Costimulatory Molecules to Improve Antitumor Immunity", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 179, no. 11, 2012, pages 7365 - 17, XP055159186, ISSN: 1110-7243 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12214012B2 (en) 2013-12-19 2025-02-04 Immutep S.A.S. Combined preparations for the treatment of cancer
US10736940B2 (en) 2013-12-19 2020-08-11 Immutep S.A.S. Combined preparations for the treatment of cancer
US10874713B2 (en) 2015-01-09 2020-12-29 Immutep S.A.S. Combined preparations for the treatment of cancer or infection
US11684654B2 (en) 2015-01-09 2023-06-27 Immutep S.A.S. Combined preparations for the treatment of cancer or infection
US10940181B2 (en) 2015-01-09 2021-03-09 Immutep S.A.S. Combined preparations for the treatment of cancer or infection
WO2016110593A1 (fr) * 2015-01-09 2016-07-14 Immutep S.A.S. Préparations combinées pour le traitement d'un cancer ou d'une infection
US10758611B2 (en) 2015-02-06 2020-09-01 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
AU2016215175B2 (en) * 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US10780161B2 (en) 2015-02-06 2020-09-22 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
EP3253876A4 (fr) * 2015-02-06 2018-09-19 Heat Biologics, Inc. Vecteur co-exprimant un vaccin et des molécules co-stimulantes
US10683357B2 (en) 2015-05-29 2020-06-16 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
US11466092B2 (en) 2015-05-29 2022-10-11 Bristol-Myers Squibb Company Antibodies against OX-40 and uses thereof
US9644032B2 (en) 2015-05-29 2017-05-09 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
US11648223B2 (en) * 2016-06-10 2023-05-16 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US10882908B2 (en) 2016-10-11 2021-01-05 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11993651B2 (en) 2016-10-11 2024-05-28 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US12187795B2 (en) 2016-10-11 2025-01-07 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination

Similar Documents

Publication Publication Date Title
WO2015131176A1 (fr) Compositions, procédés et trousses pour le traitement du cancer
Showalter et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy
JP6457940B2 (ja) 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
JP6858558B2 (ja) 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬
US20130071403A1 (en) Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
Melssen et al. Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer
US9539299B2 (en) Combination therapy with WT1 peptide vaccine and temozolomide
JP2019203035A (ja) がんの治療のための組合せ調製物
JP2024507283A (ja) 抗腫瘍薬を調製するための免疫療法薬と併用でのｐｐａｒ－デルタ阻害剤の使用
US20230256066A1 (en) Pharmaceutical composition for use in the treatment of cancer
CN111249272B (zh) 茶多酚在作为免疫检查点抑制剂及制备用于抗肿瘤的药物中的应用
US20190241660A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
Li et al. Tumor-targeted chemoimmunotherapy with immune-checkpoint blockade for enhanced anti-melanoma efficacy
Peng et al. The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment
AU2017440798C1 (en) Improved treatment of cancer
CN117323428A (zh) 一种天然糖分子Xu5P作为肿瘤免疫治疗佐剂的应用
WO2019043170A1 (fr) Polythérapie à base de hsp70
WO2023141229A2 (fr) Régimes viraux oncolytiques pour le traitement du cancer
HK40021263A (en) Nk-92 cells and il-15 agonist combination therapy
BR122024006008A2 (pt) Preparações combinadas para o tratamento de câncer ou infecção

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15756024

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15756024

Country of ref document: EP

Kind code of ref document: A1